Therefore, SHP2 inhibition may diminish the upstream signaling from RTK and impair KRAS protein activation, leading to a broad enhancement of the effect of KRASG12C inhibitors on KRASG12C-mutant cancer cells. Here, KRAS is linked to cancer.